ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 195 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.55 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $10,961,155 | -32.7% | 845,116 | -9.5% | 0.00% | -33.3% |
Q1 2024 | $16,296,396 | +85.1% | 933,356 | -0.2% | 0.00% | +50.0% |
Q4 2023 | $8,802,989 | -17.9% | 935,493 | -2.5% | 0.00% | 0.0% |
Q3 2023 | $10,722,151 | -48.6% | 959,906 | -1.5% | 0.00% | -50.0% |
Q2 2023 | $20,860,228 | -40.2% | 974,777 | +12.9% | 0.00% | -42.9% |
Q1 2023 | $34,912,499 | -15.0% | 863,316 | -2.2% | 0.01% | -22.2% |
Q4 2022 | $41,083,208 | -17.9% | 883,130 | -8.4% | 0.01% | -18.2% |
Q3 2022 | $50,023,000 | +13.6% | 964,407 | +3.6% | 0.01% | +22.2% |
Q2 2022 | $44,022,000 | -33.4% | 931,291 | +0.3% | 0.01% | -25.0% |
Q1 2022 | $66,061,000 | -12.7% | 928,093 | -8.3% | 0.01% | 0.0% |
Q4 2021 | $75,689,000 | +38.9% | 1,012,164 | +5.5% | 0.01% | +20.0% |
Q3 2021 | $54,483,000 | +90.8% | 959,048 | +47.8% | 0.01% | +100.0% |
Q2 2021 | $28,554,000 | -10.2% | 648,802 | +0.6% | 0.01% | -16.7% |
Q1 2021 | $31,807,000 | +217.8% | 644,914 | +171.3% | 0.01% | +200.0% |
Q4 2020 | $10,009,000 | -11.9% | 237,729 | -4.2% | 0.00% | 0.0% |
Q3 2020 | $11,355,000 | -11.2% | 248,041 | -2.6% | 0.00% | -33.3% |
Q2 2020 | $12,787,000 | -3.8% | 254,660 | -1.5% | 0.00% | -25.0% |
Q1 2020 | $13,298,000 | -8.1% | 258,566 | +10.4% | 0.00% | +33.3% |
Q4 2019 | $14,476,000 | -0.3% | 234,298 | -3.0% | 0.00% | 0.0% |
Q3 2019 | $14,518,000 | -26.5% | 241,647 | +3.3% | 0.00% | -40.0% |
Q2 2019 | $19,749,000 | -10.6% | 234,037 | +1.1% | 0.01% | 0.0% |
Q1 2019 | $22,101,000 | +29.6% | 231,380 | -3.9% | 0.01% | 0.0% |
Q4 2018 | $17,055,000 | -13.8% | 240,803 | +4.0% | 0.01% | 0.0% |
Q3 2018 | $19,792,000 | -23.7% | 231,596 | +3.4% | 0.01% | -28.6% |
Q2 2018 | $25,955,000 | +67.2% | 223,943 | +16.7% | 0.01% | +75.0% |
Q1 2018 | $15,521,000 | +32.0% | 191,830 | -4.3% | 0.00% | +33.3% |
Q4 2017 | $11,757,000 | +28.5% | 200,357 | +2.5% | 0.00% | +50.0% |
Q3 2017 | $9,151,000 | +30.0% | 195,523 | -0.1% | 0.00% | 0.0% |
Q2 2017 | $7,041,000 | +21.6% | 195,712 | +4.1% | 0.00% | 0.0% |
Q1 2017 | $5,789,000 | -9.2% | 187,940 | -1.2% | 0.00% | 0.0% |
Q4 2016 | $6,375,000 | +31.1% | 190,311 | +4.1% | 0.00% | 0.0% |
Q3 2016 | $4,864,000 | +24.6% | 182,817 | +3.3% | 0.00% | +100.0% |
Q2 2016 | $3,904,000 | -28.7% | 177,047 | -5.0% | 0.00% | -50.0% |
Q1 2016 | $5,475,000 | -8.5% | 186,373 | +2.8% | 0.00% | 0.0% |
Q4 2015 | $5,985,000 | -6.5% | 181,269 | +2.3% | 0.00% | 0.0% |
Q3 2015 | $6,402,000 | +9.4% | 177,159 | +36.2% | 0.00% | 0.0% |
Q2 2015 | $5,850,000 | +58.3% | 130,039 | +7.8% | 0.00% | +100.0% |
Q1 2015 | $3,696,000 | -39.7% | 120,676 | +0.1% | 0.00% | -50.0% |
Q4 2014 | $6,129,000 | +27.7% | 120,533 | -0.7% | 0.00% | 0.0% |
Q3 2014 | $4,800,000 | +97.4% | 121,322 | +114.9% | 0.00% | +100.0% |
Q2 2014 | $2,431,000 | +18.6% | 56,443 | +10.2% | 0.00% | 0.0% |
Q1 2014 | $2,049,000 | +40.3% | 51,239 | -4.2% | 0.00% | – |
Q4 2013 | $1,460,000 | +28.6% | 53,513 | +8.0% | 0.00% | – |
Q3 2013 | $1,135,000 | +378.9% | 49,536 | +269.7% | 0.00% | – |
Q2 2013 | $237,000 | – | 13,398 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 519,035 | $60,156,000 | 15.36% |
Matarin Capital Management, LLC | 201,703 | $23,377,378,000 | 1.69% |
ARMISTICE CAPITAL, LLC | 124,000 | $14,372,000 | 0.94% |
Sapphire Star Partners LP | 7,803 | $904,000 | 0.93% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 98,631 | $11,431,000 | 0.83% |
FARALLON CAPITAL MANAGEMENT LLC | 1,075,000 | $124,593,000 | 0.77% |
Granahan Investment Management | 100,670 | $11,668,000 | 0.70% |
Virtus ETF Advisers LLC | 6,577 | $762,000 | 0.67% |
AlphaMark Advisors, LLC | 11,115 | $1,288,000 | 0.52% |
Ativo Capital Management LLC | 15,029 | $1,742,000 | 0.48% |